Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sedative Hypnotic Class Labeling Warns Of Sleep-Driving And “Complex” Behaviors

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requests manufacturers of 13 sleep aids, including Ambien, Lunesta and Rozerem, to update labeling to advise of adverse events.

You may also be interested in...



Somaxon’s Silenor Could Launch In Early ’09 Pending Partnering Discussions

Somaxon submits an NDA for the insomnia medication, setting it up for potential FDA approval in December, firm tells "The Pink Sheet" DAILY.

Somaxon’s Silenor Could Launch In Early ’09 Pending Partnering Discussions

Somaxon submits an NDA for the insomnia medication, setting it up for potential FDA approval in December, firm tells "The Pink Sheet" DAILY.

Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says

Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.

Related Content

Topics

UsernamePublicRestriction

Register

PS065755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel